Combination Therapies Based on PD-1 or PD-L1 Blockade
|
|
- Susan Charles
- 6 years ago
- Views:
Transcription
1 Combination Therapies Based on PD-1 or PD-L1 Blockade Melanoma Bridge Naples, Italy December 4, 214 Mario Sznol- Yale University (in Absentia)
2 Summary of Anti-PD-1/PD-L1 Activity in Metastatic Melanoma Nivolumab Treatment-Naive Nivolumab (post ipilimumab) Nivolumab (prior Rx, not ipi) Pembrolizumab Ipi-Naive Objective Response Rates Median Duration of Response Median PFS Median Survival 1/2/3 year survival 4% (CR = 7.6%) NR 5.1 months NR 73%/x/x 26-32% NR NA NA 7%/x/x 32% 23 months 4 months 17 months 63%/48%/42% 4% NR 5.6 months NR 74%/x/x Pembrolizumab (post ipilimumab) 21-28% NR months 6mth 34-38% NR 65%/x/x
3 Possible Mechanisms for Innate Resistance to PD-1/PD-L1 Blockade No tumor antigen specific T-cells in tumor microenvironment Don t exist or; Blocked from entry into tumor Insufficient tumor antigen specific T-cells in tumor microenvironment Dysfunctional tumor antigen specific T-cells in tumor microenvironment Other checkpoints present in addition to PD1-PD-L1 pathway Dysfunction driven by checkpoints other than PD1-PD-L1 pathway Other mechanisms of T cell suppression IDO, TGF-beta, Treg, etc. Loss of tumor antigen presentation Innate tumor cell resistance to immune mediated killing
4 Combinations Based on PD-1/PD-L1 Blockade Multiple combinations supported by animal models Vaccines Cytokines (IL-15, IL-21, IFN-alfa, ) Immune checkpoints CTLA-4 LAG-3, TIM-3, B7-H3? Co-stimulatory agents 4-1BB, OX4, CD27,. Adoptive Cell Transfer Inhibitors of infiltrating suppressive MDSC and type 2 macrophages Enzyme based suppression- IDO Treg inhibition Targeted agents Chemotherapy Radiation therapy Anti-angiogenesis agents HDAC Inhibitors No human data yet to reliably predict best combination for individual patient
5 Synergistic Activity with Anti-PD-1 and Anti- CTLA-4 Antibodies Combination of Non-Efficacious Doses of anti-pd1 and anti-ctla-4 Antibodies is Efficacious in Mouse Model median tumor volume mm3 Dosing Control actla-4 MAb apd-1 MAb Combination apd-1 + actla days Provided by Alan Korman, BMS Rationale: Different roles in T cell Differentiation- Compensatory upregulation Anti-CTLA4 elimination of tumor Treg Anti-CTLA4 induced tumor T cell infiltration
6 Phase 1 CA29-4 Cohorts Cohort 1 (N = 14) Nivo.3 + Ipi 3 Q3W x 4 Q3W Nivo.3 x 4 Nivo.3 + Ipi 3 Q12W x 8 Concurrent Therapy Cohort 2 (N = 17) Cohort 3 (N = 6) Cohort 2a (N = 16) Nivo 1 + Ipi 3 Nivo 3 + Ipi 3 Nivo 3 + Ipi 1 Q3W x 4 Q3W x 4 Q3W x 4 Nivo 1 Q3W x 4 Nivo 1 + Ipi 3 Nivo 3 Q3W x 4 Nivo 3 + Ipi 3 Nivo 3 Q3W x 4 Nivo 3 + Ipi 1 Q12W x 8 Q12W x 8 Q12W x 8 Cohort 8 (N = 41) Nivo 1 + Ipi 3 Q3W x 4 Nivo 3 Q2W x 48 Sequenced Therapy Cohort 6 (N = 17) Cohort 7 (N = 16) Prior standard ipilimumab therapy 4 12 weeks from last dose Nivo 1 Nivo 3 Q2W x 48 Q2W x 48 All dose units are mg/kg. Results from Cohorts 6 and 7 (sequenced treatment cohorts ipilimumab followed by nivolumab) were reported previously (Kluger et al. ESMO 214) Ipi = ipilimumab; Nivo = nivolumab; Q2W = every 2 weeks; Q3W = every 3 weeks; Q12W = every 12 weeks 6
7 Baseline Characteristics Cohorts 1 3 (N = 53)* Cohort 8 (N = 41)* Median age, years (range) 57 (22 79) 55 (22 8) Male, n (%) 6 44 ECOG performance status, n (%) 1 Not reported Lactate dehydrogenase level, n (%) Upper limit of the normal range >Upper limit of the normal range Systemic cancer therapy, n (%) Immunotherapy BRAF inhibitor Number of prior systemic cancer therapies, n (%) *All treated patients JUNE 214 data analysis. ECOG = Eastern Cooperative Oncology Group. 7
8 Activity Summary Cohort(s) Nivo (mg/kg) + Ipi (mg/kg) N b ORR, a % CR, % Aggregate Clinical Activity Rate, % 8% Tumor Burden Reduction at 36 Weeks, c % a d All Concurrent Cohorts a Per modified World Health Organization (mwho) criteria, [CR+PR]/Nx1. b Number of response-evaluable patients. c Best overall response. d Cohort 8 using the phase 2/3 trial dose schedule, started November 213. JUNE 214 data analysis 8
9 Maximum Response in Target Lesions Maximum Response From Baseline in Target Lesion (%) Patient Patients Cohorts % patients had 8% reduction in target lesion Cohort 8 29% patients had 8% reduction in target lesion JUNE 214 data analysis. April 214 data analysis 9
10 Metastatic melanoma from anal mucosal primary, Cohort 2: response to ipilimumab 3 mg/kg + nivolumab 1 mg/kg; Received a single dose of combination due to early onset uveitisresponded to high dose steroids
11 Metastatic melanoma from anal mucosal primary, Cohort 2: response to ipilimumab 3 mg/kg + nivolumab 1 mg/kg; Received a single dose of combination due to early onset uveitisresponded to high dose steroids
12 Metastatic melanoma from anal primary Relapse after approx. 2 years, re-induction with 4 combination doses to near CR; No recurrence of uveitis Sienkiewicz, Dina, L Unit#: MR Acc#: E DOB: 1/7/1967 F/46 YEAR H Yale New Haven Hospital Sienkiewicz, Dina, L CT NP 256 LightSpeed VCT Unit#: MR CT CHEST ABDOMEN PELVIS W IV CONTRAST Acc#: E CHEST - ABDOMEN - PELVIS WITHOUT AND/OR WITH DOB: 1/7/1967 6/5/214 1:42:41 PM F/46 YEAR Tech: DM H Yale New Haven Hospital CT NP 256 LightSpeed VCT CT CHEST ABDOMEN PELVIS W IV CONTRAST 6.1 CHEST - ABDOMEN - PELVIS WITHOUT AND/OR WITH 8/16/214 1:53:26 AM Tech: mt R L R L FFS Tilt: KVp: W: 4 C: 4 Z: 1.53 HELICAL MODE /1:42:41 PM ORAL OMNI & 85CC OMNI 35 F cm NI: 135 ASIR: SS2 FFS THK: 5 Tilt: XY: 8.6 KVp: Compressed 8:1 W: 49 C: 39 Z: 1.22 IM: 22 SE: 61 HELICAL MODE /1:53:26 AM Page: 22 of 51 ORAL OMNI & 85CC OMNI 35 F cm NI: 135 ASIR: SS2 THK: 5 XY: Compressed 8:1 IM: 25 SE: 61 Page: 25 of 54
13 Cohort 8, Ipilimumab + nivolumab, response at 12 weeks Prior therapy with HD-IL2, multiple resections, Vemurafenib, and RT; LDH > 2 at baseline; LDH nearly normal within 3 weeks
14 Yale Ipi/Nivo Cohorts 1-3 N=25 Confirmed PR/CR 1 (4%) 7 ongoing near CR 1 CR ->PD at approx. 2.5 years -> reinduced -> near CR 1 PD in node and then in brain, DOD at approx. 2 years 1 PD DOD at > 4 years after multiple therapies Of 15 PD/unconfirmed OR: Mixed response (early brain met), then later bowel mets now NED with gamma knife RT + surgery Mixed Resp at 12 weeks -> off due to tox (lipase) CR with further ipi alone, single local recurrence resected upr -> off due to LFTs PD on steroids stable PR with further ipi alone 1 prolonged irpr PD reinduction-> alive with PD 1 inevaluable response in brain mets and small systemic DZ (lung/liver) -2 brain mets RX with GK-RT now NED > 1 year 1 irsd PD reinduced at approx 3.5 years 1 SD PD PR to TIL 1 total deaths (6 non-responders) 4 at dose level 1 1 ocular primary Follow-up 2 years 8/1 PR/CR remain in CR/near CR (one required re-induction at 2.5 years) 4 with mixed response or transient response remain with NED with additional ipi alone, ipi + surgery, or GKRT + surgery 1 with SD x 1 year remains progression-free after TIL 2 with waxing and waning disease and slow progression on continued therapy and reinduction Tail of curve at 5% survival?
15 1 9 Overall Survival 1-yr OS 94% 2-yr OS 88% Lowest survival in cohort 1 Dose response for nivo versus patient selection OS (%) Cohort 8 (N=41) 1-yr OS 85% 2-yr OS 79% Cohort 2 (N=17) Cohorts 1 3 (N=53) Died/Treated Median OS (95% CI) Cohort 2 4/17 NR (26.8 NR) Cohorts /53 NR (39.7 NR) 1 Cohort 8 8/41 NR (1.5 NR) Patients at Risk Cohort 2 (Nivo 1 + Ipi 3) Cohorts 1 3 Cohorts 8 (Nivo 1 + Ipi 3) Month Cohort 8 uses the same dosing schedule that is being tested in the phase 3 trial (CA29-67) JUNE 214 data analysis. 15
16 ORR and Tumor Burden Change by BRAF Mutation Status Cohort(s) [N * ] Evaluable Sample, N BRAF WT ORR, n/n (%) BRAF MT 1 3 [53] 51 18/39 (46) 3/12 (25) 8 [41] 39 1/27 (37) 6/12 (5) * Number of patients treated. MT=mutant (BRAFT V6 mutation positive); WT=wild-type (BRAF V6 mutation negative). Maximum Response From Baseline in Target Lesion (%) Cohorts 1 3 Cohort JUNE 214 data analysis. BRAF MT BRAF WT BRAF Unknown 16
17 ORR and Tumor Burden Change by PD-L1 Status Cohort(s) [N * ] Evaluable Sample, N ORR, n/n (%) PD-L1 Positive PD-L1 Negative 1 3 [53] 37 8/14 (57) 8/23 (35) 8 [41] 21 / 8/21 (38) * Number of patients treated. 5% cut-off, tumor cell surface staining. None of the 21 evaluable patient samples was test positive for PD-L1 by 5% tumor cell surface staining cutoff Cohorts 1 3 Cohort 8 Maximum Response From Baseline in Target Lesion (%) PD-L1+ PD-L1- PD-L1 Unknown JUNE 214 data analysis. 17
18 Treatment-Related AEs Reported in 15% of Patients* Patients with an Cohorts 1 3 (N=53) Cohort 8 (N=41) event, % Any Grade Grade 3/4 Grade 5 Any Grade Grade 3/4 Grade 5 All drug-related Rash Pruritus Fatigue Diarrhea Nausea Lipase increased AST increased Pyrexia ALT increased Amylase increased Vitiligo 15 7 Abdominal pain Arthralgia 9 2 *Listing adverse events reported in 15% of patients in cohorts 1 3 or in cohort 8, sorted by any grade frequency in cohort 1 3; One patient died due to grade 5 multi-organ failure related to study treatment in cohort 8 ALT = alanine aminotransferase; AST = aspartate aminotransferase. JUNE 214 data analysis. 18
19 Treatment-Related Immune-Mediated* AEs Patients with an event, % Cohorts 1 3 (N=53) Cohort 2 (N=17) Cohort 8 (N=41) Any Grade Grade 3/4 Any Grade Grade 3/4 Any Grade Grade 3/4 Skin Gastrointestinal Hepatic Endocrine Pulmonary Renal Hypersensitivity /Infusion Reaction Standard safety guidelines available to manage immune-mediated AEs with immune suppressing medication *Immune-mediated adverse events are events with potential immunologic causes and those that require more frequent monitoring or intervention with immune suppression or hormone replacement JUNE 214 data analysis. 19
20 PD-1/PD-L1 Blockade + anti-ctla-4 Next Steps and Questions Randomized trials versus ipilimumab (69) and versus ipilimumab or nivolumab (67) were completed Concurrent versus sequential Gene expression (Dhodapkar et al, SITC 214) suggest concurrent administration produces unique biological effects Management of adverse events Predictive biomarkers? Biology of acquired resistance? Safe triple combinations? (anti-vegf, others) 2
21 Non-Immunotherapy VEGF/VEGFRi RT Molecular targets ChemoRx Vaccines Cytokines Antigen Presenting Cell or Tumor T-lymphocyte Function (excluding Treg) Peptide-MHC T cell receptor Signal 1 CD8/CD86 (B7.1, B7.2) CD28/CTLA-4 Stimulatory/inhibitory CEACAM-1 and TIM-3 CEACAM-1 inhibitory CD7 CD27 stimulatory LIGHT HVEM stimulatory HVEM BTLA, CD16 inhibitory PD-L1 (B7-H1) PD-1 and CD8 Inhibitory (Th1) PD-L2 (B7-DC) PD1 and? Inhibitory (Th2) or stimulatory OX4L OX4 stimulatory 4-1BBL CD137 stimulatory CD4 CD4L Stimulatory to DC/APC B7-H3? Inhibitory or stimulatory B7-H4? inhibitory PD-1H (Vista)? inhibitory GAL9 TIM-3 inhibitory MHC class II LAG-3 inhibitory B7RP1 ICOS stimulatory MHC class I KIR Inhibitory or stimulatory GITRL GITR stimulatory CD48 2B4 (CD244) inhibitory HLA-G, HLA-E ILT2, ILT4; NKG2a inhibitory MICA/B, ULBP-1, -2, -3, and -4+- NKG2D Inhibitory or stimulatory CD2 CD2R inhibitory CD155 TIGIT/CD226 Inhibitory/stimulatory IDO Treg MDSC Macrophages TGF-beta In our melanoma gene expression database, high levels of: CEACAM-1 B7-H3 CD2 CD155 (PVR)
22 TIM3
23 41BB + anti-pdl1 Hirano et al, Cancer Res, Feb, 25
24 Ipilimumab (anti-ctla-4) Tremelimumab (anti-ctla-4) Bevacizumab IFNs RCC/melanoma IL-21 terminated? IL-2 (proposed) anti-lag3 anti-kir peptide vaccines Oncolytic viruses (Tvec) Anti-OX4 (proposed) Anti-CD27 Anti-CD137 Treg inhibitors - mogamulizumab Adoptive Cell Therapy Dabrafenib +/- Trametinib Vemurafenib +/-Cobimetinib RT PD-1 Pathway Blockade Combinations in Development
25 Response to Ipi-Nivo June 213 July 213 Feb 214 Pt recently progressed on ACT*
26 Conclusions If phase 3 trials confirm early data, anti-pd-1 + anti-ctla4 will become SOC for metastatic melanoma (wtbraf and mbraf) Following for long term survival Toxicity high but manageable (similar to ipi 1 mg/kg) Approaches to improve ipi/nivo not immediately obvious Multiple combinations supported by animal model data But clinical correlative data not yet available to select best regimens for subsets of patients Clinical endpoints for studies may need to evolve 3-year survival rates? Durable CR or near CR?
27 Credits CA29-4 Jedd Wolchok Margaret Callahan Harriet Kluger Michael Atkins John Kirkwood Mary Ruisi Ashok Gupta Alan Korman Many others
Melanoma. Il parere dell esperto. V. Ferraresi. Divisione di Oncologia Medica 1
Melanoma Il parere dell esperto V. Ferraresi Divisione di Oncologia Medica 1 MELANOMA and ESMO 2017.what happens? New data and updates ADJUVANT THERAPY with CHECKPOINT INHIBITORS (CA209-238 trial) AND
More informationImmunotherapy for the Treatment of Melanoma. Marlana Orloff, MD Thomas Jefferson University Hospital
Immunotherapy for the Treatment of Melanoma Marlana Orloff, MD Thomas Jefferson University Hospital Disclosures Immunocore and Castle Biosciences, Consulting Fees I will be discussing non-fda approved
More informationImmunotherapy, an exciting era!!
Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy
More informationImmunotherapy Treatment Developments in Medical Oncology
Immunotherapy Treatment Developments in Medical Oncology A/Prof Phillip Parente Director Cancer Services Eastern Health Executive MOGA ATC Medical Oncology RACP www.racpcongress.com.au Summary of The Desired
More informationIII Sessione I risultati clinici
10,30-13,15 III Sessione I risultati clinici Moderatori: Michele Maio - Valter Torri 10,30-10,45 Melanoma: anti CTLA-4 Vanna Chiarion Sileni Vanna Chiarion Sileni IOV-IRCCS,Padova Vanna.chiarion@ioveneto.it
More informationNew Systemic Therapies in Advanced Melanoma
New Systemic Therapies in Advanced Melanoma Sanjay Rao, MD FRCPC Medical Oncologist (BCCA-CSI) Clinical Assistant Professor, UBC Faculty of Medicine SON Fall Update October 22, 2016 Disclosures Equity
More informationOptimizing Immunotherapy New Approaches, Biomarkers, Sequences and Combinations Immunotherapy in the clinic Melanoma
Optimizing Immunotherapy New Approaches, Biomarkers, Sequences and Combinations Immunotherapy in the clinic Melanoma Dr. J.L.Manzano S. Oncología Médica H. Germans Trias i Pujol, ICO-Badalona PRBB Auditorium,
More informationTerapia Immunomodulante e Target Therapies nel Trattamento del Melanoma Metastatico
Terapia Immunomodulante e Target Therapies nel Trattamento del Melanoma Metastatico Pier Francesco Ferrucci Direttore, Unità di Oncologia Medica del Melanoma Istituto Europeo di Oncologia - Milano Pisa,
More informationRenal Cell Carcinoma: Systemic Therapy Progress and Promise
Renal Cell Carcinoma: Systemic Therapy Progress and Promise Michael B. Atkins, M.D. Deputy Director, Lombardi Comprehensive Cancer Ctr Georgetown University Medical Center Everolimus Rini, Campbell, Escudier.
More informationPhase 1 Study Combining Anti-PD-L1 (MEDI4736) With BRAF (Dabrafenib) and/or MEK (Trametinib) Inhibitors in Advanced Melanoma
Phase 1 Study Combining Anti-PD-L1 (MEDI4736) With BRAF (Dabrafenib) and/or MEK (Trametinib) Inhibitors in Advanced Melanoma Abstract #3003 Ribas A, Butler M, Lutzky J, Lawrence D, Robert C, Miller W,
More informationOvercoming Toxicities Associated with Novel Checkpoint Inhibitor Immunotherapy. Tara C. Gangadhar, MD Assistant Professor of Medicine ICI Boston 2016
Overcoming Toxicities Associated with Novel Checkpoint Inhibitor Immunotherapy Tara C. Gangadhar, MD Assistant Professor of Medicine ICI Boston 2016 Overcoming toxicity A new context for evaluating toxicity
More informationUnderstanding Checkpoint Inhibitors: Approved Agents, Drugs in Development and Combination Strategies. Michael A. Curran, Ph.D.
Understanding Checkpoint Inhibitors: Approved Agents, Drugs in Development and Combination Strategies Michael A. Curran, Ph.D. MD Anderson Cancer Center Department of Immunology Disclosures I have research
More informationMariano Provencio Servicio de Oncología Médica Hospital Universitario Puerta de Hierro. Immune checkpoint inhibition in DLBCL
Mariano Provencio Servicio de Oncología Médica Hospital Universitario Puerta de Hierro Immune checkpoint inhibition in DLBCL Immunotherapy: The Cure is Inside Us Our immune system prevents or limit infections
More information6/7/16. Melanoma. Updates on immune checkpoint therapies. Molecularly targeted therapies. FDA approval for talimogene laherparepvec (T- VEC)
Melanoma John A Thompson MD July 17, 2016 Featuring: Updates on immune checkpoint therapies Molecularly targeted therapies FDA approval for talimogene laherparepvec (T- VEC) 1 Mechanism of ac-on of Ipilimumab
More informationImmunoterapia e melanoma maligno metastatico: siamo partiti da li. Vanna Chiarion Sileni Istituto Oncologico Veneto
Immunoterapia e melanoma maligno metastatico: siamo partiti da li Vanna Chiarion Sileni Istituto Oncologico Veneto Vanna.chiarion@iov.veneto.it Metastatic Melanoma Available Treatment: 197 217 Zelboraf
More informationImmunotherapy for Melanoma. Caroline Robert, MD, PhD Gustave Roussy and Université Paris Sud Villejuif, France
Immunotherapy for Melanoma Caroline Robert, MD, PhD Gustave Roussy and Université Paris Sud Villejuif, France Overall Survival for Metastatic Melanoma Proportion Alive 1.0 0.8 0.6 0.4 0.2 Survival data
More informationImmunotherapy for Melanoma. Michael Postow, MD Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center
Immunotherapy for Melanoma Michael Postow, MD Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center Conflicts of Interest Bristol-Myers Squibb: -Research support -Participated
More informationImmune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic
Immune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic Conflicts of Interest Research Funding from Bristol Myers
More informationUpdate on Immunotherapy in Advanced Melanoma. Ragini Kudchadkar, MD Assistant Professor Winship Cancer Institute Emory University Sea Island 2017
Update on Immunotherapy in Advanced Melanoma Ragini Kudchadkar, MD Assistant Professor Winship Cancer Institute Emory University Sea Island 2017 1 Outline Adjuvant Therapy Combination Immunotherapy Single
More informationONCOS-102 in melanoma Dr. Alexander Shoushtari. 4. ONCOS-102 in mesothelioma 5. Summary & closing
ONCOS-102 in melanoma Dr. Alexander Shoushtari 4. ONCOS-102 in mesothelioma 5. Summary & closing 1 Preliminary data from C824 Activating the Alexander Shoushtari, MD Assistant Attending Physician Melanoma
More informationNew paradigms for treating metastatic melanoma
New paradigms for treating metastatic melanoma Paul B. Chapman, MD Melanoma Clinical Director Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center, New York 20 th Century Overall
More informationMelanoma: From Chemotherapy to Targeted Therapy and Immunotherapy. What every patient needs to know. James Larkin
Melanoma: From Chemotherapy to Targeted Therapy and Immunotherapy What every patient needs to know James Larkin Melanoma Therapy 1846-2017 Surgery 1846 Cytotoxic Chemotherapy 1946 Checkpoint Inhibitors
More informationMelanoma Clinical Trials and Real World Experience
Melanoma Clinical Trials and Real World Experience Paul Lorigan University of Manchester Manchester, UK www.christie.nhs.uk/melanoma Melanoma Bridge, Naples 214 New Benchmarks for Phase II Trials OS at
More informationImmunotherapy for Metastatic Malignant Melanoma. Dr Daniel A Vorobiof Sandton Oncology Centre Johannesburg
Immunotherapy for Metastatic Malignant Melanoma Dr Daniel A Vorobiof Sandton Oncology Centre Johannesburg Survival in Melanoma by Stage Proportion Surviving 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 Stage
More informationImmune Checkpoints. PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich
Immune Checkpoints PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich Activation of T cells requires co-stimulation Science 3
More informationImmunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania
Immunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania Overview Background Immunotherapy clinical decision questions
More informationAACR 2018 Investor Meeting
AACR 218 Investor Meeting April 16, 218 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking statements for
More informationCheckpoint regulators a new class of cancer immunotherapeutics. Dr Oliver Klein Medical Oncologist ONJCC Austin Health
Checkpoint regulators a new class of cancer immunotherapeutics Dr Oliver Klein Medical Oncologist ONJCC Austin Health Cancer...Immunology matters Anti-tumour immune response The participants Dendritc cells
More informationNew Therapeutic Approaches to Malignant Melanoma
2018 Master Class for Oncologists New Therapeutic Approaches to Malignant Melanoma F. Stephen Hodi, M.D. Dana-Farber Cancer Institute, Boston, MA Disclosure I have nothing to disclose. Off Label/Investigational
More informationUpdate on Melanoma Treatment. Tara C Mitchell, MD
Update on Melanoma Treatment Tara C Mitchell, MD Overview Immune therapy update Targeted therapy update New concepts in treating melanoma What is the immune system? A complex network of protective cells
More informationIMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS
IMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS Dr Elizabeth Smyth Cambridge University Hospitals NHS Foundation Trust ESMO Gastric Cancer Preceptorship Valencia 2018 DISCLOSURES Honoraria for advisory role
More informationEndogenous and Exogenous Vaccination in the Context of Immunologic Checkpoint Blockade
Endogenous and Exogenous Vaccination in the Context of Immunologic Checkpoint Blockade Jedd Wolchok Ludwig Center for Cancer Immunotherapy Memorial Sloan-Kettering Cancer Center MEMORIAL SLOAN- KETTERING
More informationCheckpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015
Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib
More informationASCO Annual Meeting 2017 Bart Neyns MD PhD, UZ Brussel. 20th Post-ASCO Meeting, 24th June 2016
IMMUNOTHERAPY @the ASCO Annual Meeting 2017 Bart Neyns MD PhD, UZ Brussel 20th Post-ASCO Meeting, 24th June 2016 FAS-L Cancer Testis Ag Differentiation Ag Neo-antigens PD-1 CTL CD8+ Tcell CTLA-4 CD28 B7.1/B7.2
More informationImmunotherapy of Melanoma Sanjiv S. Agarwala, MD
Immunotherapy of Melanoma Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA Overview Metastatic Melanoma
More informationCheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer
CheckMate 12: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer Abstract 31 Hellmann MD, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE,
More informationCurrent Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology
Current Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology Overview Melanoma incidence and prevention Approach to surgical management of early melanoma Landscape of Advanced Melanoma Therapy
More informationMelanoma: Immune checkpoints
ESMO Preceptorship Programme Immuno-Oncology Siena, July 04-05, 2016 Melanoma: Immune checkpoints Michele Maio Medical Oncology and Immunotherapy-Department of Oncology University Hospital of Siena, Istituto
More informationFocus on Immunotherapy as a Targeted Therapy. Brad Nelson, PhD BC Cancer, Victoria, Canada FPON, Oct
Focus on Immunotherapy as a Targeted Therapy Brad Nelson, PhD BC Cancer, Victoria, Canada FPON, Oct 18 2018 Disclosures I have nothing to disclose that is relevant to this presentation. Immunology @ Deeley
More informationCytokines: Interferons, Interleukins and Beyond. Michael B. Atkins, MD Georgetown-Lombardi Comprehensive Cancer Center
Cytokines: Interferons, Interleukins and Beyond Michael B. Atkins, MD Georgetown-Lombardi Comprehensive Cancer Center Disclosures Advisory Boards: Bristol-Myers Squibb,Amgen, Novartis, Alkermes, Infinity,
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationASCO 2014 Highlights*
ASCO 214 Highlights* Investor Meeting June 2, 214 *American Society of Clinical Oncology, May 3 June 3, 214 Forward-Looking Information During this meeting, we will make statements about the Company s
More informationImmune Checkpoint Blockade against Malignancy. Blocking Self-inflicted Inhibitions?
Immune Checkpoint Blockade against Malignancy Blocking Self-inflicted Inhibitions? IGNORANT T CELL ANERGIC T CELL APOPTOTIC T CELL (DELETED) Insufficient antigen/ lack of co-stimulatory signals Unsuccessful
More informationSummary... 2 MELANOMA AND OTHER SKIN TUMOURS... 3
ESMO 2016 Congress 7-11 October, 2016 Copenhagen, Denmark Table of Contents Summary... 2 MELANOMA AND OTHER SKIN TUMOURS... 3 Long-term results show adjuvant therapy with ipilimumab improves OS in high
More informationIMMUNOTARGET THERAPY: ASPETTI GENERALI
IMMUNOTARGET THERAPY: ASPETTI GENERALI Alessandro Minisini Dipartimento di Oncologia Azienda Ospedaliero Universitaria Udine Verona, 19 settembre 2015 HALLMARKS OF CANCER Douglas Hanahan, Robert A. Weinberg,
More informationImmunotherapy in Lung Cancer
Immunotherapy in Lung Cancer Jamie Poust Pharm. D., BCOP Oncology Pharmacist University of Colorado Hospital Objectives Describe the recent advances in immunotherapy for patients with lung cancer Outline
More informationBristol-Myers Squibb, Braine-l Alleud, Belgium; 12 MD Anderson Cancer Center, Houston, TX, USA
3531 Combination of nivolumab (NIVO) + ipilimumab (IPI) in the treatment of patients (pts) with deficient DNA mismatch repair (dmmr)/high microsatellite instability (MSI-H) metastatic colorectal cancer
More informationNuovi approcci immunoterapici nel trattamento del Melanoma: Background immunologico.
Nuovi approcci immunoterapici nel trattamento del Melanoma: Background immunologico. Andrea Anichini Human Tumors Immunobiology Unit Dept. of Experimental Oncology and Molecular Medicine Immune checkpoint
More informationPrinciples and Application of Immunotherapy for Cancer: Advanced Melanoma
In Partnership With Principles and Application of Immunotherapy for Cancer: Advanced Melanoma This program is supported by educational grants from Genentech and Merck. About These Slides Users are encouraged
More informationImmune checkpoint blockade in lung cancer
Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data
More informationTreatment of Tumors Resistant to PD-1 inhibitors
Treatment of Tumors Resistant to PD-1 inhibitors Harriet Kluger, MD Professor of Medicine (Medical Oncology), Yale School of Medicine Deputy Section Chief, Medical Oncology Associate Cancer Center Director
More informationImmunotherapy in lung cancer. Saurabh maji
Immunotherapy in lung cancer Saurabh maji Worldwide, lung cancer is the most common cause of cancerrelated deaths Small cell lung cancer (SCLC) presents with widespread disease at the time of diagnosis,
More informationBeyond BRAFi/MEKi: Combination and Sequencing Approaches for in Patients with Metastatic BRAF V600 Mutant Melanoma:
Beyond BRAFi/MEKi: Combination and Sequencing Approaches for in Patients with Metastatic BRAF V600 Mutant Melanoma: Michael B. Atkins, M.D. Deputy Director Georgetown-Lombardi Comprehensive Cancer Center
More informationAdvances in Cancer Immunotherapy for Solid Tumors Expert Perspectives on The New Data Sunday, June 5, 2016
Advances in Cancer Immunotherapy for Solid Tumors Expert Perspectives on The New Data Sunday, June 5, 2016 Supported by an independent educational grant from AstraZeneca Not an official event of the 2016
More informationPresentation Number: LBA18_PR. Lecture Time: 09:15-09:27. Speakers: Heinz-Josef J. Lenz (Los Angeles, US) Background
LBA18_PR - Durable Clinical Benefit With Nivolumab (NIVO) Plus Low-Dose Ipilimumab (IPI) as First-Line Therapy in Microsatellite Instability-High/Mismatch Repair Deficient (MSI-H/dMMR) Metastatic Colorectal
More informationASCO 2014: The Future is Here. What I Will Talk About. George W. Sledge MD Stanford University School of Medicine
ASCO 214: The Future is Here George W. Sledge MD Stanford University School of Medicine What I Will Talk About Two paths to a Cure Slicing the pie MelMng the snowflake The Past Isn t Dead Improving PaMent
More informationImmunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know
Immunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know Jeffrey Weber, MD, PhD Laura and Isaac Perlmutter Cancer Center NYU Langone Medical Center New York, New York What Is the Current
More informationLa revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD
La revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD Hospital Universitario Clinico San Carlos Medical Oncology Department Thoracic & Urological Cancer Unit Complutense University
More informationImmunotherapy for Renal Cell Carcinoma. James Larkin
Immunotherapy for Renal Cell Carcinoma James Larkin Disclosures Institutional research support: BMS, MSD, Novartis, Pfizer Consultancy (all non-remunerated): Eisai, BMS, MSD, GSK, Pfizer, Novartis, Roche/Genentech
More informationTHE FUTURE OF IMMUNOTHERAPY IN COLORECTAL CANCER. Prof. Dr. Hans Prenen, MD, PhD Oncology Department University Hospital Antwerp, Belgium
THE FUTURE OF IMMUNOTHERAPY IN COLORECTAL CANCER Prof. Dr. Hans Prenen, MD, PhD Oncology Department University Hospital Antwerp, Belgium DISCLAIMER Please note: The views expressed within this presentation
More informationCombination Approaches in Melanoma: A Balancing Act
Combination Approaches in Melanoma: A Balancing Act Antoni Ribas, MD, PhD Jonsson Comprehensive Cancer Center University of California Los Angeles Los Angeles, California Advances in the Treatment of Metastatic
More informationMELANOMA METASTASICO: NUEVAS COMBINACIONES. Dr Ana Arance MD PhD Oncología Médica Hospital Clínic Barcelona
MELANOMA METASTASICO: NUEVAS COMBINACIONES Dr Ana Arance MD PhD Oncología Médica Hospital Clínic Barcelona Summary of OS accross clinical trials in patients with metastatic melanoma Ugurel et al. Eur J
More informationAdverse effects of Immunotherapy. Asha Nayak M.D
Adverse effects of Immunotherapy Asha Nayak M.D None Financial Disclosures Objectives Understand intensity of the AEs. Understanding unique side-effects. Develop effective monitoring and management guidelines.
More informationInnovations in Immunotherapy - Melanoma. Systemic Therapies October 27, 2018 Charles L. Bane, MD
Innovations in Immunotherapy - Melanoma Systemic Therapies October 27, 2018 Charles L. Bane, MD Melanoma Prognosis Survival at 10 years Stage I: 90% Stage II: 60% Stage III: 40% Stage IV: 10% 2 Indications
More informationPriming the Immune System to Kill Cancer and Reverse Tolerance. Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics
Priming the Immune System to Kill Cancer and Reverse Tolerance Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics Learning Objectives Describe the role of the immune system in cancer
More informationII sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese
II sessione Immunoterapia oltre la prima linea Alessandro Tuzi ASST Sette Laghi, Varese AGENDA Immunotherapy post-chemo ( true 2/3L ) Immunotherapy in oncogene addicted NSCLC (yes/no? when?) Immunotherapy
More informationEvolving Treatment Strategies in the Management of Metastatic Melanoma: Novel Therapies for Improved Patient Outcomes. Disclosures
Evolving Treatment Strategies in the Management of Metastatic Melanoma: Novel Therapies for Improved Patient Outcomes Fall Managed Care Forum November 11, 2016 Matthew Taylor, M.D. Disclosures Consulting/Advisory
More informationCoxsackievirus A21: The basic facts
Phase II CALM Extension study: Intratumoral CAVATAK TM increases immune- cell infiltrates and up- regulates immune- checkpoint molecules in the microenvironment of lesions from advanced melanoma padents
More informationInterleukin-2 Single Agent and Combinations
Interleukin-2 Single Agent and Combinations Michael K Wong MD PhD Norris Cancer Center University of Southern California mike.wong@med.usc.edu Disclosures Advisory Board Attendance Merck Bristol Myers
More informationThe Really Important Questions Current Immunotherapy Trials are Not Answering
The Really Important Questions Current Immunotherapy Trials are Not Answering David McDermott, MD Beth Israel Deaconess Medical Center Dana Farber/Harvard Cancer Center Harvard Medical School PD-1 Pathway
More informationNew Frontiers in Metastatic Melanoma: A Closer Look at the Role of Immunotherapy
New Frontiers in Metastatic Melanoma: A Closer Look at the Role of Immunotherapy Philip Friedlander MD PhD Director of Melanoma Medical Oncology Program Assistant Professor Division of Hematology Oncology
More information2/16/2018. The Immune System and Cancer. Fatal Melanoma Transferred in a Donated Kidney 16 years after Melanoma Surgery
C007: Immunology of Melanoma: Mechanisms of Immune Therapies Delphine J. Lee, MD, PhD Chief and Program Director, Dermatology, Harbor UCLA Medical Center Principal Investigator, Los Angeles Biomedical
More informationMedical Treatment for Melanoma Sanjiv S. Agarwala, MD
Medical Treatment for Melanoma Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA Disclosures None Overview
More informationMelanoma- Fighting the Dark Side
Melanoma- Fighting the Dark Side Anna C. Pavlick, BSN, MSc, DO, MBA Professor of Medicine and Dermatology Director, NYU Melanoma Program Director, NYU Clinical Trials Office NYU Perlmutter Cancer Center
More informationOut of 129 patients with NSCLC treated with Nivolumab in a phase I trial, the OS rate at 5-y was about 16 %, clearly higher than historical rates.
6th Meeting on external quality assessment in molecular pathology, Naples, May 12-13, 2017 Overview of clinical development of checkpoint inhibitors in solid tumors Pr Jaafar BENNOUNA University of Nantes
More informationManagement of Brain Metastases Sanjiv S. Agarwala, MD
Management of Brain Metastases Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA, USA Incidence (US):
More informationMelanoma in Focus: Update on Novel Therapy, Emerging Agents, and Optimizing Patient Care Presentation 1
Presentation 1 The following is a transcript from a web-based CME -certified multimedia activity. Interactivity applies only when viewing the activity online. This activity is supported by educational
More informationNew Avenues for the development and evaluation of therapy: Complex, multi-pronged, not one size fitting all
New Avenues for the development and evaluation of therapy: Complex, multi-pronged, not one size fitting all Antoine Yver MD MSC Senior VP & Head Oncology Global Medicines Development AstraZeneca, Gaithersburg
More informationImmunotherapy of HNC: immune mechanisms and therapeutic targets
Immunotherapy of HNC: immune mechanisms and therapeutic targets Ourania Tsitsilonis, MD, PhD Department of Biology National & Kapodistrian University of Athens What does the Immune System see in Cancer?
More informationImmuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017
Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The goal of this MONTHLY
More informationCheckpointinhibitoren in der Uro-Onkologie. Carsten Grüllich
Checkpointinhibitoren in der Uro-Onkologie Carsten Grüllich 07.02.15 T-cell Aktivierung und Regulation T cell Costimulation Recognition MHC I Peptide b2m mrna Tumorantigen Tumor Pardoll Nature Rev Cancer
More informationThe Current Status of Immune Checkpoint Inhibitors: Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb
The Current Status of Immune Checkpoint Inhibitors: A Global Overview of the Field Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb Immune Checkpoint Inhibitors Conference, March
More informationCheckpoint-Inhibitoren beim Lungenkarzinom. Dr. Helge Bischoff Thoraxklinik Heidelberg
Checkpoint-Inhibitoren beim Lungenkarzinom Dr. Helge Bischoff Thoraxklinik Heidelberg Survival (%) First-Line: Polychemotherapy vs 9387 patients 778 patients in studies with platinum chemotherapy 1-year
More informationDurable Response Rate in High Grade Glioma: an Emerging Endpoint for Immunotherapeutics. Timothy Cloughesy, MD University of California, Los Angeles
Durable Response Rate in High Grade Glioma: an Emerging Endpoint for Immunotherapeutics Timothy Cloughesy, MD University of California, Los Angeles Disclosure 2 FDA Endpoints for the Approval of Cancer
More informationThe Immunotherapy of Oncology
The Immunotherapy of Oncology The 30-year Overnight Success Story M Avery, BIOtech Now 2014 Disclosures: Geoffrey R. Weiss, M.D. None The History A. Chekov: It has long been noted that the growth of malignant
More informationFifteenth International Kidney Cancer Symposium November 4-5, 2016 Marriott Miami Biscayne Bay, Miami, Florida, USA
The following presentation should not be regarded as an endorsement of a particular product/drug/technique by the speaker. The presentation topics were assigned to the speakers by the scientific committee
More informationPresenter Disclosure Information
Presenter Disclosure Information Tara C. Gangadhar, M.D. The following relationships exist related to this presentation: Research funding (Institution): Incyte Corporation and Merck & Co., Inc Preliminary
More informationDisclosure Information. Mary L. Disis
Disclosure Information Mary L. Disis I have the following financial relationships to disclose: Consultant for: VentiRx, Celgene, Emergent, EMD Serono Speaker s Bureau for: N/A Grant/Research support from:
More informationCTLA-4 regulates pathogenicity of antigen-specific autoreactive T cells by cell-intrinsic and -extrinsic mechanisms
Class 15, BBS821: Control of pathogenic self-reactive T cells by co-inhibitory molecules, J. Kang Oct 29, 2015 CTLA-4 regulates pathogenicity of antigen-specific autoreactive T cells by cell-intrinsic
More informationTHE ROLE OF TARGETED THERAPY AND IMMUNOTHERAPY IN THE TREATMENT OF ADVANCED CERVIX CANCER
Gynecologic Cancer InterGroup Cervix Cancer Research Network THE ROLE OF TARGETED THERAPY AND IMMUNOTHERAPY IN THE TREATMENT OF ADVANCED CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum
More informationPTAC meeting held on 5 & 6 May (minutes for web publishing)
PTAC meeting held on 5 & 6 May 2016 (minutes for web publishing) PTAC minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and
More informationDisclosures Information Brendan D. Curti, MD
The MITCI (Phase 1b) study: A novel immunotherapy combination of intralesional Coxsackievirus A21 and systemic ipilimumab in advanced melanoma patients with or without previous immune checkpoint therapy
More informationOverview: Immunotherapy in CNS Metastases
Overview: Immunotherapy in CNS Metastases Manmeet Ahluwalia, MD, FACP Miller Family Endowed Chair in Neuro-Oncology Director Brain Metastasis Research Program Cleveland Clinic Disclosures Consultant- Monteris
More informationSupplementary Online Content
Supplementary Online Content Powles T, O Donnell PH, Massard C, et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 openlabel
More informationNon-Small Cell Lung Cancer Webinar. Thursday, September 13, p.m. EDT
Non-Small Cell Lung Cancer Webinar Thursday, September 13, 2018 1 2 p.m. EDT 1 2 Webinar Faculty Julie R. Brahmer, MD Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Patrick Forde, MD Johns
More informationMelanoma: Therapeutic Progress and the Improvements Continue
Melanoma: Therapeutic Progress and the Improvements Continue David W. Ollila, MD Professor of Surgery Jesse and James Millis Professor of Melanoma Research May 20, 2016 Disclosures: NONE Outline 2016 Therapeutic
More informationConversations in Oncology. November Kerry Hotel Pudong, Shanghai China
Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not
More informationApproaches To Treating Advanced Melanoma
Approaches To Treating Advanced Melanoma Suraj Venna, MD Medical Director, Melanoma and Cutaneous Oncology Inova Schar Cancer Institute Associate Professor, VCU Fairfax VA Disclosures No relevant disclosures
More informationCancer immunity and immunotherapy. General principles
1 Cancer immunity and immunotherapy Abul K. Abbas UCSF General principles 2 The immune system recognizes and reacts against cancers The immune response against tumors is often dominated by regulation or
More informationOverall Survival (OS) Analysis From an Expanded Access Program (EAP) of Nivolumab (NIVO) in Combination with Ipilimumab (IPI) in Patients with Advanced Melanoma (MEL) David Hogg, Paul B. Chapman, 2 Mario
More information